BRIEF-FDA approves expanded use of ENBREL to treat children with chronic moderate-to-severe plaque psoriasis

* Amgen Inc - FDA has approved SBLA for expanded use of ENBREL to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.